We therefore aim to characterize the effect of MK-2206 alone as well as in combination with BCL-2 inhibitor venetoclax on B-ALL cell lines and primary samples in a protective co-culture environment. The gene discussed is BCL2; the disease is acute lymphoblastic leukemia.